Skip to main content

Digital Diabetes Management: Transforming Connected Healthcare

Page 1

MARKET RESEARCH BRIEFING | FORECAST 2026 –2035

Digital Diabetes Management Market Connected monitoring, smart insulin delivery and AI software converge into a USD 66.86 Bn absolute opportunity through 2035. For investors, strategy teams & B2B decision-makers

2025 market size

2026 estimate

2035 forecast

CAGR 2026–2035

USD 22.82 Bn

USD 26.27 Bn

USD 93.13 Bn

15.1%

Base year

Forecast start

~3.5× the 2026 base

Double-digit growth

Executive summary

Market size trajectory (USD Bn)

• CGMs have moved from a niche Type 1 tool

93.13

into a broad consumer and prevention

+USD 66.86 Bn 2026→2035

product. • Software & Data (19.0% CAGR) outpaces

26.27

22.82

hardware as payers demand integrated, data-driven programs.

2025

2026

• Type 2 diabetes leads end users: USD 9.59

2035

Bn (2025) → USD 38.17 Bn (2035).

Market share leaders (2025) North America — revenue share ~44%

Connected Glucose Monitoring — product ~46%

INDUSTRY ECOSYSTEM AI R&D

›

Devices

› Manufacturing ›

Copyright © Next Move Strategy Consulting

Data mgmt

›

Distribution

›

Regulation

Source: NMSC Digital Diabetes Management Report · 01


02 | GROWTH DRIVERS & OPPORTUNITIES

Prevalence, OTC access and AI dosing power a 15.1% CAGR Impact on CAGR, 2026–2035 (percentage points) Rising Type 2 diabetes & prediabetes prevalence

+4.4 FDA clearance of over-the-counter CGM

+3.1 Expanding payer reimbursement

+2.5 AI-integrated insulin dosing optimization

+1.9 High out-of-pocket costs in emerging markets

−2.1

Highest-growth segments (CAGR 2026–2035)

20.4%

19.9%

19.7%

19.0%

Wellness & Prevention

Prediabetes

Software Subscription

Software & Data

USD 0.91 → 5.59 Bn

USD 2.05 → 12.11 Bn

Demand drivers

USD 3.19 → 18.63 Bn

Whitespace opportunities

• OTC CGM: Abbott Lingo & Libre Rio (FDA, 2024) open the non-insulin and wellness population. • AI decision support: DexCom Smart Basal

(2025) embeds dosing guidance in CGM. • Smart pens: lower-cost bridge between

USD 3.88 → 21.42 Bn

01 02 03

Payer-funded prediabetes screening

ahead of diagnosis Smart pen + CGM data fusion for multiple-daily-injection patients Employer-sponsored programs expanding the Services segment

injections and pumps. Abbott FY2025 CGM sales exceeded USD 7.5

Bn, with Q4 alone at USD 2.0 Bn. Copyright © Next Move Strategy Consulting

Source: NMSC Digital Diabetes Management Report · 02


02 | REGIONAL OPPORTUNITIES

North America leads on scale; Asia-Pacific leads on growth Growth opportunity map (USD Bn, 2025 → 2035)

higher CAGR lower

North America

Europe

FASTEST GROWING

10.05 → 36.32

5.93 → 23.28

Asia-Pacific

CAGR 13.6% · ~44% share

CAGR 14.6%

Broad CGM reimbursement, OTC access

National health system adoption

4.56 → 23.28

18.0% CAGR 2026–2035

Latin America

Middle East & Africa

Rising Type 2 prevalence

1.37 → 6.52

0.91 → 3.73

and mobile health adoption

CAGR 17.1%

CAGR 15.1%

Private healthcare & digital investment

Government chronic-care initiatives

Fastest-growing countries (CAGR)

Largest country markets (USD Bn) 21.4%

India

in China & India

Country

2025

2035

China

18.9%

U.S.

8.65

31.06

South Korea

17.7%

China

1.55

8.71

Brazil

16.9%

Germany

1.78

6.66

Japan

16.2%

UK

1.66

6.29

Canada

1.40

5.26

India

0.68

4.66

Investor takeaway Asia-Pacific adds ~USD 18.7 Bn by 2035 and matches Europe in size; entry strategies should favor price-sensitive connected meters and app-based coaching, as out-of-pocket costs remain the key restraint (−2.1 pts). Copyright © Next Move Strategy Consulting

Source: NMSC Digital Diabetes Management Report · 03


03 | COMPETITIVE SCENARIO

Integrated hardware–software ecosystems hold the structural edge Competitive positioning matrix

Software & services integration →

Service-led platforms

Basis of competition Device accuracy CGM & patch-pump precision

Ecosystem leaders Abbott Medtronic

Teladoc Omada

Software integration Patient apps & clinician platforms Reimbursement depth Payer coverage breadth

DexCom Insulet Market structure

Device specialists

Moderately consolidated — top 10 hold majority share

Hardware depth (CGM, pumps, accuracy) →

Key strategic moves (partnerships & regulatory milestones over large M&A) Jan 2024 · Partnership

2024 · Launch

2025 · Innovation

2025 · Expansion

Abbott CGM integrated

FDA clears Abbott Lingo

DexCom Smart Basal AI

Quebec RAMQ extends

with Insulet Omnipod

& Libre Rio for OTC use

dosing optimizer cleared

Dexcom coverage to

Horizon AID

Type 2

Key companies profiled (selected of 20) Abbott

DexCom

Medtronic

Insulet

Tandem

Roche

Ypsomed

Sinocare

Teladoc

Omada

Senseonics

Glooko

Virta Health

LifeScan

Diabeloop

Copyright © Next Move Strategy Consulting

Positioning qualitative, per NMSC archetypes · 04


04 | LET'S CONNECT

Thank You Connect with our analysts for in-depth insights, segment-level data and strategic guidance on the Digital Diabetes Management market.

Contact us Official website

Phone

Email

www.nextmsc.com

+1 857 758 5017

info@nextmsc.com

Click here for the complete report → nextmsc.com/report/digital-diabetes-management-market-hc5415 Market share of top 10 companies · 20 company profiles · 38 countries

Follow us LinkedIn

Facebook

LinkedIn

YouTube

Facebook

Copyright © Next Move Strategy Consulting

Twitter / X

YouTube

Twitter

Instagram

Instagram

05


Turn static files into dynamic content formats.

Create a flipbook
Digital Diabetes Management: Transforming Connected Healthcare by rohi345537 - Issuu